2016

Memo Therapeutics AG announces completion of a first commercial project validating its proprietary MemoMAB™ antibody technology platform.
Basel/Zurich, …

MEMO’s poster introducing the MemoMAB™ technology platform for the banking and screening of human immunoreceptor libraries was selected for the …

MEMO’s abstract has been accepted for Poster Discussion presentation during the ESMO Symposium on Immuno-Oncology – Advances in cancer immunotherapy; …

Memo Therapeutics made it to the top 100 of Swiss startups for the second time in a row and is …

2016 Meeting Schedule
 
Sept 27-28: SACHS 16th Annual Biotech in Europe Forum, Basel
MEMO’s CEO Dr. A. Mäder will …

MEMO has started a first client project based on its rbMemoMAB™ antibody discovery technology.
About rbMemoMAB™.

The CTI/KTI project “Banking of human antibody repertoires for therapeutic use” was approved and starts in June 2016. The project …

Meet MEMO through the partnering system at Bio 2016 in San Francisco. See the meeting schedule for more details.

The guardian’s recent article “Ebola treatment using antibody from survivor’s blood passes first trial” describes the therapeutic use of an …

MEMO has reached proof of concept with its rbMemoMAB™ process. First monoclonal antibody candidates could be isolated from an immunized …